AI GxP validation for regulated life sciences
AI Governance

AI in Pharmacovigilance: Case Processing and Signal Detection

PV volumes grow every year and headcount does not. Where AI genuinely helps with intake, coding and triage, why signal detection is harder than it looks, and the causality judgement that cannot be delegated.

Cybroscape Technologies5 min read

Key takeaway

PV volumes grow every year and headcount does not. Where AI genuinely helps with intake, coding and triage, why signal detection is harder than it looks, and the causality judgement that cannot be delegated.

Pharmacovigilance has a volume problem that compounds. Case numbers rise with every product, every market and every new reporting channel, while the regulatory clocks stay exactly where they are. Headcount rarely grows at the same rate.

That makes PV one of the strongest candidates for automation in this industry, and also one where the line between help and harm is drawn with unusual clarity.

Intake, coding and triage

Case intake. Reading an incoming report — an email, a form, a call transcript, a literature abstract — and extracting the four elements that make a valid case: patient, reporter, product, event. This is structured extraction from messy text, which is what these systems do best.

Duplicate detection. Recognising that the same event has arrived twice through different channels, which is harder than exact matching and genuinely tedious by hand.

MedDRA coding suggestions. Proposing preferred terms for a reported event. A coder confirms. Consistency of coding across a large case series is exactly the sort of thing humans do unevenly and machines do steadily.

Seriousness and expectedness triage. Proposing a provisional classification so the cases that drive a 15-day clock surface first. Proposing, not deciding.

Narrative drafting from the structured case data, for a reviewer to finish — see safety narratives.

Why signal detection is harder than it looks

Finding a new safety signal in spontaneous report data is a genuinely difficult statistical problem, and adding a model does not make it easy.

Spontaneous reporting is biased in known ways: under-reporting varies by product, market and how long a drug has been available; media attention creates reporting spikes unrelated to incidence; and you never know the denominator. Disproportionality methods have always lived with this. A model trained on the same data inherits every one of those biases, and expresses them more confidently.

Where it does help is in the sifting that precedes the judgement: grouping related reports, surfacing clusters a quarterly review might miss, and pulling together everything already known about a product-event pair so a safety physician spends their time assessing rather than assembling.

A system that says "here are nine reports sharing an unusual pattern, and here is the existing literature" is useful. One that says "this is a signal" is making a judgement that belongs to a person.

What cannot be delegated

  • Causality assessment. Whether the product plausibly caused the event is a medical judgement with regulatory consequences, made by a qualified person.
  • Final seriousness determination, because it sets a reporting obligation and a clock.
  • Signal validation and the decision to act — label change, risk minimisation, communication.
  • Benefit-risk conclusions in periodic reports.
  • The QPPV's responsibilities, which attach to a named individual by regulation.

Also worth stating plainly: a missed valid case is a reportable compliance failure, not an efficiency problem. That asymmetry should drive your acceptance criteria — an intake system that occasionally creates a false case is an irritation; one that occasionally drops a real one is a finding. See acceptance criteria for AI.

Wider programme context in pharmacovigilance services and GxP AI.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

AI drafts
AI-drafted
Source linked
Your reviewerApprove and signSend back with comments
Signed record
  • Signer’s name
  • Date and time
  • Meaning of the signature
  • Entry in the audit trail
The AI never approves its own work
Where the AI stops: it drafts and links each statement to its source. A qualified person reviews, edits and signs. Only the signed version becomes the record.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.
ai pharmacovigilanceai adverse event processingai safety signal detectionautomated case intake pv
FAQ

Frequently Asked Questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

Where does AI help in pharmacovigilance?

Case intake — extracting patient, reporter, product and event from messy text; duplicate detection across channels; MedDRA coding suggestions for a coder to confirm; provisional seriousness and expectedness triage so cases driving a 15-day clock surface first; and drafting narratives from structured case data for a reviewer to finish.

Can AI detect safety signals reliably?

Not on its own. Spontaneous reporting is biased in known ways — under-reporting varies by product and market, media attention creates spikes, and the denominator is unknown. A model trained on that data inherits every bias and expresses it more confidently. It helps with the sifting that precedes the judgement, not the judgement.

What cannot be delegated in PV?

Causality assessment, final seriousness determination because it sets a reporting clock, signal validation and the decision to act, benefit-risk conclusions in periodic reports, and the QPPV's responsibilities, which attach to a named individual by regulation.

How should acceptance criteria be set for PV automation?

Around the asymmetry: a missed valid case is a reportable compliance failure, while a false case is an irritation. Criteria should be far stricter on missed cases than on false positives, and the test set should be sized around detecting the rare miss.

Is automated case intake acceptable to regulators?

Automation of intake and coding with qualified human confirmation is widely used. What matters is that a person remains accountable for the medical judgements, that the audit trail shows who confirmed what, and that you can demonstrate the system is not systematically dropping valid cases.

Keep reading

All articles
AI GovernanceYour Data Probably Isn't Ready for AI. Here's How to TellThe step nobody budgets for. How to judge whether your deviations, batch records and documents can actually support an AI project, what to fix first, and why a model trained on inconsistent history learns the inconsistency. · 6 min readAI GovernanceAI in the QC Lab: Where It Helps and Where It Must Not DecideChromatography review, OOS triage, stability trending and method transfer are the lab's slowest work. What AI can genuinely take on, what has to stay an analyst's call, and why lab data integrity history makes this area sensitive. · 6 min readAI GovernanceFour factors for judging AI risk in GMP: uncertainty, complexity, model influence, detectabilityA severity score where everything comes out high changes nothing. The four considerations EMA's workshop report names produce a more honest assessment. · 7 min readAI GovernanceThe EU AI Act and life sciences: less than you fear, plus one thing you missedMost GxP AI is not high-risk under the EU AI Act. Medical device AI and AI used in hiring or performance decisions are, and the AI literacy duty has applied to every company using AI since February 2025. · 3 min readAI GovernanceCan You Use Microsoft Copilot or ChatGPT in a GxP Environment?The question every quality team is being asked. Where general-purpose AI assistants are fine in a regulated company, where they are not, why they cannot produce Part 11 records, and how to write a policy people will follow. · 7 min readAI GovernanceThe White House SI Accord: What "Internal Controls and Layers of Audits" Actually MeansThe industry accord signed alongside the order is voluntary and, in the President's words, morally binding. What its commitments would mean if taken seriously, and how they compare with what GMP has required of computerised systems for decades. · 5 min readAI GovernanceWhy Quality Teams Resist AI, and What Actually Changes Their MindsThe resistance is usually rational, and treating it as a training problem makes it worse. What quality professionals are actually objecting to, which arguments land, and the one demonstration that moves people. · 6 min readFDA21 CFR Part 11 GxP Compliance: What It Requires, What It Looks Like, and How to Get There21 CFR Part 11 section by section (11.1 to 11.300), what the FDA enforces under its 2003 scope and application guidance, what compliant records and signatures look like, and the ten failure modes inspectors find most often. · 11 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.